Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib with Adjuvant Endocrine Therapy in HR+ Breast Cancer
NCT02040857Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Jan 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02040857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040857.